Boston cancer firm axes 75% of staff after FDA rejection
A Boston cancer firm is laying off most of its staff after bad news from the U.S. Food and Drug Administration.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health Management | Pharmaceuticals